HUP9900681A2 - TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban - Google Patents

TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban

Info

Publication number
HUP9900681A2
HUP9900681A2 HU9900681A HUP9900681A HUP9900681A2 HU P9900681 A2 HUP9900681 A2 HU P9900681A2 HU 9900681 A HU9900681 A HU 9900681A HU P9900681 A HUP9900681 A HU P9900681A HU P9900681 A2 HUP9900681 A2 HU P9900681A2
Authority
HU
Hungary
Prior art keywords
ribavirin
activated
lymphocytes
modulation
analogs
Prior art date
Application number
HU9900681A
Other languages
English (en)
Inventor
Devron Averett
Kandasamy Ramasamy
Robert Tam
Original Assignee
Icn Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9900681(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.
Publication of HUP9900681A2 publication Critical patent/HUP9900681A2/hu
Publication of HUP9900681A3 publication Critical patent/HUP9900681A3/hu
Publication of HU220105B publication Critical patent/HU220105B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány tárgyát eljárásők képezik nemvirális betegségben szenvedő,elfőjtőtt Th1-termeléssel és főkőzőtt Th2-termeléssel jellemezhetőcitőkinprőfillal rendelkező páciens kezelésére, tővábbá Th1- és Th2-válaszreakció befőlyásőlására emberi páciens aktivált T-sejtjeiben,Ribavirin alkalmazásával. A találmány szerinti megőldás előnyösenalkalmazható a limfőkinexpresszió instabilitásainak (egyensúlyiállapőttól való eltérésének) kezelésére, Ribavirin és Ribavirin-analógők felhasználásával. ŕ
HU9900681A 1996-01-23 1997-01-21 Ribavirin alkalmazása TH1- és TH2- válaszreakció befolyásolására szolgáló készítmények előállítására HU220105B (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P 1997-01-17 1997-01-17
PCT/US1997/000600 WO1997026883A1 (en) 1996-01-23 1997-01-21 Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Publications (3)

Publication Number Publication Date
HUP9900681A2 true HUP9900681A2 (hu) 1999-07-28
HUP9900681A3 HUP9900681A3 (en) 1999-12-28
HU220105B HU220105B (hu) 2001-10-28

Family

ID=26712784

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900681A HU220105B (hu) 1996-01-23 1997-01-21 Ribavirin alkalmazása TH1- és TH2- válaszreakció befolyásolására szolgáló készítmények előállítására

Country Status (21)

Country Link
EP (1) EP0879056B1 (hu)
KR (1) KR100298158B1 (hu)
CN (1) CN1190198C (hu)
AT (1) ATE216886T1 (hu)
BR (1) BR9707154A (hu)
CA (1) CA2246162C (hu)
CZ (1) CZ293584B6 (hu)
DE (1) DE69712316T2 (hu)
DK (1) DK0879056T3 (hu)
ES (1) ES2172764T3 (hu)
HU (1) HU220105B (hu)
IL (1) IL125088A0 (hu)
NO (1) NO983372L (hu)
NZ (1) NZ330784A (hu)
PL (1) PL187439B1 (hu)
PT (1) PT879056E (hu)
RU (1) RU2186569C2 (hu)
SI (1) SI9720013A (hu)
SK (1) SK283342B6 (hu)
UA (1) UA46815C2 (hu)
WO (1) WO1997026883A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254911A1 (en) * 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
DE69737935T2 (de) 1996-10-25 2008-04-03 Minnesota Mining And Manufacturing Co., St. Paul Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten
CZ20012519A3 (cs) * 1999-01-29 2002-05-15 Icn Pharmaceuticals, Inc. Nukleosid pro pouľití jako léčivo pro léčení odezvy imunitního systému v expozici
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2002013855A2 (en) * 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
MX2008011360A (es) * 2006-03-09 2009-03-03 Om Pharma Compuestos inmunodulares y tratamiento de enfermedades relacionadas con la sobreproduccion de citoquinas inflamatorias.
SG172696A1 (en) 2006-06-12 2011-07-28 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
HUE041509T2 (hu) 2011-12-22 2019-05-28 Janssen Biopharma Inc Szubsztituált nukleozidok, nukleotidok és ezek analógjai
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
CA2894542C (en) 2012-12-21 2023-10-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9862743B2 (en) 2013-10-11 2018-01-09 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232706T2 (de) * 1991-05-01 2002-11-28 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen

Also Published As

Publication number Publication date
DE69712316D1 (en) 2002-06-06
CN1190198C (zh) 2005-02-23
SI9720013A (sl) 1999-06-30
HUP9900681A3 (en) 1999-12-28
WO1997026883A1 (en) 1997-07-31
PT879056E (pt) 2002-10-31
EP0879056A1 (en) 1998-11-25
NO983372L (no) 1998-09-21
PL328003A1 (en) 1999-01-04
SK283342B6 (sk) 2003-06-03
ATE216886T1 (de) 2002-05-15
CA2246162A1 (en) 1997-07-31
AU1747897A (en) 1997-08-20
IL125088A0 (en) 1999-01-26
NZ330784A (en) 1999-02-25
NO983372D0 (no) 1998-07-22
SK100498A3 (en) 2001-03-12
KR100298158B1 (ko) 2001-09-06
PL187439B1 (pl) 2004-07-30
UA46815C2 (uk) 2002-06-17
CA2246162C (en) 2000-04-04
AU700642B2 (en) 1999-01-14
EP0879056A4 (en) 1999-01-13
EP0879056B1 (en) 2002-05-02
CZ293584B6 (cs) 2004-06-16
ES2172764T3 (es) 2002-10-01
HU220105B (hu) 2001-10-28
RU2186569C2 (ru) 2002-08-10
DK0879056T3 (da) 2002-08-19
BR9707154A (pt) 1999-05-25
CN1209747A (zh) 1999-03-03
DE69712316T2 (de) 2003-01-02
KR19990081930A (ko) 1999-11-15
CZ232998A3 (cs) 1999-04-14

Similar Documents

Publication Publication Date Title
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
BR9910251A (pt) Estimulação hematopoiética
ATE500808T1 (de) Onkolytische virustherapie
DK184186A (da) Terapeutisk praeparat til behandling af virussygdomme
DE3578176D1 (de) Verbindungen fuer die induktion von in vivo und in vitro produktion von cytokinen.
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
CY1112439T1 (el) Μεταλλαγμα fsh-γλυκοζυλιωσης
SE9101815L (sv) Behandling av sjukdom foerbunden med hiv-infektioner
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
WO2002076313A8 (fr) Extenseur de l'os maxillaire
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
DE59704194D1 (de) Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
DK383488D0 (da) Humant papillomavirus type 41, dets dna og deraf kodede proteiner
PT1150981E (pt) Composto nucleosidico terapeutico
IT1241993B (it) Uso di alfa-chetoglurato di arginina e/oppure di diarginina nella preparazione di composizioni farmaceutiche per il trattamento di deficit psicologici, immunologici e dell'apprendimento
UA30949A (uk) Спосіб комплексного лікування гнійно-запальних захворювань щелепно-лицьової області
NO884718D0 (no) Liggeunderlag til bruk i sykeseng for pasienter med liggesaar, brannsaar eller lignende.
KR20030077743A (ko) In½
IT8205203A0 (it) Strumento medicale monouso atto per determinare la natura delle affezioni allergiche, tramite cutireazione.
ES2165788B1 (es) Empleo de la levadura de cerveza en la elaboracion de un medicamento para el tratamiento del sindrome x fragil.
IT8667614A0 (it) Impiego della elastase nel trattamento terapeutico di disturbi della irrorazione sanguigna periferica

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: VALEANT RESEARCH & DEVELOPMENT, US

MM4A Lapse of definitive patent protection due to non-payment of fees